Your browser doesn't support javascript.
loading
Setting-up an Ebola vaccine trial in a remote area of the Democratic Republic of the Congo: Challenges, mitigations, and lessons learned.
Zola Matuvanga, Trésor; Larivière, Ynke; Lemey, Gwen; De Bie, Jessie; Milolo, Solange; Meta, Rachel; Esanga, Emmanuel; Vermeiren, Paul Peter; Thys, Séverine; Van Geertruyden, Jean-Pierre; Van Damme, Pierre; Maketa, Vivi; Matangila, Junior; Mitashi, Patrick; Muhindo-Mavoko, Hypolite.
Afiliação
  • Zola Matuvanga T; Tropical Medicine Department, University of Kinshasa, Kinshasa, The Democratic Republic of the Congo; Centre for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute, University of Antwerp, Wilrijk, Belgium; Global Health Institute, Department of Family Medicine and Population Hea
  • Larivière Y; Centre for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute, University of Antwerp, Wilrijk, Belgium; Global Health Institute, Department of Family Medicine and Population Health, University of Antwerp, Wilrijk, Belgium. Electronic address: ynke.lariviere@uantwerpen.be.
  • Lemey G; Centre for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute, University of Antwerp, Wilrijk, Belgium; Global Health Institute, Department of Family Medicine and Population Health, University of Antwerp, Wilrijk, Belgium.
  • De Bie J; Centre for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute, University of Antwerp, Wilrijk, Belgium; Global Health Institute, Department of Family Medicine and Population Health, University of Antwerp, Wilrijk, Belgium.
  • Milolo S; Tropical Medicine Department, University of Kinshasa, Kinshasa, The Democratic Republic of the Congo.
  • Meta R; Tropical Medicine Department, University of Kinshasa, Kinshasa, The Democratic Republic of the Congo.
  • Esanga E; Tshuapa Provincial Health Division, The Democratic Republic of the Congo.
  • Vermeiren PP; Centre for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute, University of Antwerp, Wilrijk, Belgium; Global Health Institute, Department of Family Medicine and Population Health, University of Antwerp, Wilrijk, Belgium.
  • Thys S; Centre for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute, University of Antwerp, Wilrijk, Belgium; Global Health Institute, Department of Family Medicine and Population Health, University of Antwerp, Wilrijk, Belgium.
  • Van Geertruyden JP; Global Health Institute, Department of Family Medicine and Population Health, University of Antwerp, Wilrijk, Belgium.
  • Van Damme P; Centre for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute, University of Antwerp, Wilrijk, Belgium.
  • Maketa V; Tropical Medicine Department, University of Kinshasa, Kinshasa, The Democratic Republic of the Congo.
  • Matangila J; Tropical Medicine Department, University of Kinshasa, Kinshasa, The Democratic Republic of the Congo.
  • Mitashi P; Tropical Medicine Department, University of Kinshasa, Kinshasa, The Democratic Republic of the Congo.
  • Muhindo-Mavoko H; Tropical Medicine Department, University of Kinshasa, Kinshasa, The Democratic Republic of the Congo.
Vaccine ; 40(25): 3470-3480, 2022 05 31.
Article em En | MEDLINE | ID: mdl-35550847
Since the largest Ebola outbreak in West Africa (2013-2016) highlighted the potential threat of the Ebola virus to the world, several vaccines have been under development by different pharmaceutical companies. To obtain vaccine licensure, vaccine trials assessing the safety, immunogenicity and efficacy of new vaccines among different populations (e.g. different in age, gender, race, and ethnicity) play a crucial role. However, while this deadly disease mainly affects Central and West Africa, clinical trial regulations are becoming increasingly complex and consequently more expensive, influencing the affected low- and middle-income countries (LMICs) in performing high quality clinical trials. Consequently, the completion of such trials in LMICs takes more time and vaccines and drugs take longer to be licensed. To overcome some of the obstacles faced, the EBOVAC3 consortium, funded by the European Union's Innovative Medicines Initiative and the Coalition for Epidemic Preparedness Innovations, enabled high quality vaccine trials in Central and West Africa through extensive North-South collaborations. In this article, the encountered challenges, mitigations, recommendations and lessons learned from setting-up an Ebola vaccine trial in a remote area of the Democratic Republic of Congo are presented. These challenges are grouped into eight categories: (1) Regulatory, political and ethical, (2) Trial documents, (3) International collaborations, (4) Local trial staff, (5) Community engagement and sensitization, (6) Logistics, (7) Remoteness and climate conditions, (8) Financial. By sharing the encountered challenges, implemented mitigations and lessons learned for each of these categories, we hope to prepare and inform other researchers aspiring a well-functioning clinical trial unit in similar remote settings in LMICs. ClinicalTrials.gov identifier: NCT04186000.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença pelo Vírus Ebola / Vacinas contra Ebola / Ebolavirus Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença pelo Vírus Ebola / Vacinas contra Ebola / Ebolavirus Idioma: En Ano de publicação: 2022 Tipo de documento: Article